The paper highlighted how the platform addressed the fragmented nature of heart failure care by enabling continuous communication between hospital specialists and community healthcare providers.

Study Design and Implementation

The AZIMUTH study (FondAZione A. Gemelli IRCCS Artificial Intelligence Empowered Digital PlatforM to sUpport paTients with Heart Failure) addressed this healthcare challenge through innovative digital health technology, demonstrating how smartphone-based care could transform outcomes for heart failure patients. This multicenter, prospective study enrolled 300 heart failure patients across four leading Italian medical centers in Phases 1 and 2.

The study utilized Healthentia v3, a Class I Software as Medical Device (SaMD), as the core platform for remote patient monitoring and care delivery operating through two integrated components:

Patient Mobile Application: Patients used intuitive “widgets” for daily health monitoring, including mandatory weight and blood pressure tracking, validated questionnaires (Kansas City Cardiomyopathy Questionnaire and medication adherence assessments), and optional monitoring of heart rate, oxygen saturation, and physical activity. The app seamlessly integrated with Bluetooth-enabled devices to minimize manual entry errors.

Clinical Dashboard: Healthcare providers accessed a comprehensive platform that consolidated patient data into actionable insights, featuring real-time monitoring, intelligent alert systems based on clinical thresholds, longitudinal trend analysis, and integrated patient communication tools.

The study carefully addressed the real-world implementation by establishing clear inclusion criteria that balanced technological requirements with practical applicability. Patients required basic digital literacy or caregiver support, smartphone compatibility, and received comprehensive training during enrollment. The platform was designed for intuitive use across age groups, ensuring broad accessibility.

Proven Results

The study successfully demonstrated the effectiveness of digital health solutions in heart failure management:

Patient Engagement: Achieved the primary objective with over 70% of patients successfully engaging with the digital platform throughout the study period.

Clinical Improvements: Patients showed significantly improved medication adherence and treatment engagement compared to traditional care approaches.

Healthcare Provider Value: Clinicians reported enhanced ability to monitor patients remotely, identify early warning signs, and coordinate care more effectively.

Feasibility Confirmed: The app-based model proved both technically feasible and clinically valuable across diverse patient demographics.

Impact and Validation

AZIMUTH validated that smartphone-based care could transform outcomes for heart failure patients – a population traditionally challenged by frequent hospitalizations and complex medication regimens. The study proved that digital health solutions, when properly implemented through certified medical device platforms like Healthentia, could enhance both patient outcomes and healthcare efficiency.

The successful completion of AZIMUTH Phase 1 established a new evidence base for digital health adoption in chronic disease management, demonstrating that collaborative innovation between healthcare institutions, pharmaceutical companies, and technology providers can deliver measurable clinical value. A second paper with results from Phase II is expected soon and new partners have joined efforts in a new study named Azimusa utilizing the Azimuth care model and expanding further the scope to more medical centers in the north with more patients.

The post AZIMUTH Study: Digital Transformation in Heart Failure Care appeared first on Healthentia.

What Is B-COMPASS?

At its core, B-COMPASS helps all stakeholders in Healthcare from clinicians, caregivers, software providers, and healthcare policymakers to identify the drivers behind patient behavior. It relies on a concise set of fewer than ten questions to generate a patient profile based on five key dimensions: health consciousness, treatment needs, personal concerns, acceptance, and perceived control.

This simplicity makes it powerful. It enables the creation of tailored communication and support strategies to address the unique challenges each patient faces, ultimately aiming to improve adherence and treatment outcomes.

How Innovation Sprint Is Contributing

As a proud partner in the BEAMER project, Innovation Sprint brings deep experience in real-world data collection, behavioral modeling, and chronic disease management through our flagship Software as a Medical Device (SaMD), Healthentia.

With years of insights from managing patient journeys, particularly around non-adherence patterns, Innovation Sprint contributes to shaping and validating the B-COMPASS model with real-world scenarios. Our involvement ensures the model reflects actual patient needs and clinical realities, making it both usable and impactful in digital health platforms.

Through Healthentia, we have seen firsthand how variable patient engagement can be, and how crucial it is to adapt digital interventions to individual needs. Integrating tools like B-COMPASS enhances our ability to design adaptive programs that not only monitor but also positively influence patient behavior over time.

Why B-COMPASS Matters for SaMDs like Healthentia

Tools like B-COMPASS don’t just provide insight, they enable action. For SaMDs, this means gaining the ability to segment patients more meaningfully and respond with personalized interventions, educational content, and coaching.

The result? Increased treatment adherence, improved patient satisfaction, and reduced healthcare burden—goals at the heart of both BEAMER and Innovation Sprint’s mission.

Looking Forward

As B-COMPASS matures within the BEAMER framework, its integration into digital health ecosystems like Healthentia will further personalize chronic disease management. We believe this marks a pivotal step toward scalable, human-centered digital healthcare.

To learn more about B-COMPASS and the BEAMER project, visit https://beamerproject.eu/BEAMER-model/.

The post Enhancing Patient Adherence with B-COMPASS: A New Horizon for Digital Health Solutions appeared first on Healthentia.

Managing chronic obstructive pulmonary disease (COPD) alongside other chronic conditions (CCs) like depression requires a comprehensive and innovative approach. As part of the RE-SAMPLE research project, Healthentia, our advanced SaMD solution, addresses this challenge by integrating real-world data (RWD) to enhance disease management and improve daily life for patients. For more information about the intended use of the device and the medical modules, please consult: https://healthentia.com/medical-device/

This research-driven initiative bridges the gap between clinical research and real-world healthcare, supporting two phases of COPD and CCs management:

• Phase 1: Healthentia collects RWD to track disease progression, uncover patterns, and predict exacerbations. These insights enable proactive care, empowering healthcare providers to anticipate and address patient needs more effectively.
• Phase 2: Through its Virtual Companionship Program (VCP), the platform delivers tailored self-management tools, including lifestyle coaching, goal-setting, and real-time medical suggestions. Patients gain the confidence to manage their health actively, while healthcare providers benefit from actionable insights via a clinical dashboard. This enables personalized, adaptive care strategies, ensuring better outcomes.

Healthentia redefines the standard of COPD care in hospitals across Europe by seamlessly integrating real-world insights with technology-driven solutions. By prioritizing both patients and providers, it transforms the approach to managing not only COPD but also co-existing chronic conditions, helping patients regain control over their health and well-being.

This World COPD Day, Healthentia reaffirms its commitment to innovation, providing hope and support for millions living with COPD.

The post Transforming COPD Care with Healthentia: Empowering Patients and Providers through Real-World Insights appeared first on Healthentia.

Software as a Medical Devices (SaMD) and mobile health (mHealth) applications have revolutionized the healthcare landscape in the areas of Remote Patient Monitoring (RPM) and Digital Therapeutics (DTx). These technological advancements offer a range of benefits, from improved patient engagement and real-time monitoring to personalized treatment plans and enhanced clinical outcomes. During the continuous design, development, and validation of our medical device Healthentia, we have conducted a comprehensive systematic literature review to assess the current status and efficacy of these digital health interventions and benchmark the results with our finding from the clinical evidence we have collected from various studies. The results are rather positive, demonstrating how SaMDs like Healthentia can support the management of chronic diseases, satisfying patient safety and performance requirements.

The current landscape of SaMD and mHealth apps is characterized by rapid innovation and widespread adoption, especially after the Covid pandemic, which might have worked as a catalyst for digital transformation in digital health. SaMD refers to software intended to be used for medical purposes that perform these purposes without being part of a hardware medical device. mHealth applications, on the other hand, encompass a wide range of digital tools designed to support health and wellness through mobile devices. mHealth applications are not necessarily medical devices and therefore, they often don’t comply with the regulatory framework. Both SaMD and mHealth apps have seen significant advancements, driven by the increasing need for accessible, efficient, and patient-centric healthcare solutions. Regulatory frameworks have also evolved to keep pace with these innovations, ensuring that these technologies meet rigorous safety and efficacy standards. While the potential of SaMD and mHealth apps are immense, there are several challenges that need to be addressed to fully realize their benefits, such as data privacy concerns, integration with existing healthcare systems, and user adoption barriers.

The review involved a scientific process of identifying, selecting, and analyzing relevant studies that evaluate the effectiveness of SaMD and mHealth apps in managing chronic diseases, using the PICO (Population, Intervention, Comparison, Outcomes and Study) framework. The selected studies provide a robust evidence base, highlighting the positive impact of these technologies on patient outcomes.

This post aims to provide a comprehensive overview of the current status of SaMD and mHealth apps, highlight promising results, and discuss the potential these technologies hold for improving health outcomes and provides only an overview of a peer reviewed paper that we expect to publish in the coming months.

The safety and performances of such solutions for chronic disease patients is thoroughly discussed in various meta-analyses that have been retrieved and analyzed and include 14 meta-analyses for diabetes Type II, cardiovascular diseases, COPD and cancer. Those meta-analyses allow to identify the main clinical performances that could be expected for Healthentia to define the acceptance criteria for the risks/benefits acceptability. In addition, clinical studies originating from the selected systematic reviews were analyzed to check which features were put in place in the eHealth solutions under evaluation, allowing a comparison with those of Healthentia, resulting in prospective controlled studies on several chronic diseases:

• Diabetes Type II: 24 studies, about 1.200 patients in the intervention group
• COPD: 1 study, 36 patients
• Cancer: 3 studies, about 150 patients
• Heart diseases: 7 studies, 560 patients

Summarizing the results from these studies we provide some data both biomarkers and other clinical endpoints that demonstrate the potential:

• HbA1c level: Decreased in several of the studies.
• Physical activity & performance: Significant improvements in exercise capacity.
• Body fat: Significant improvements.
• Sleep: Significant improvements in sleep time.
• Self-care/management: Self-reported improved the self-monitoring of patients’ blood glucose levels, diet, exercise, other self-management skills, and knowledge of the disease.
• Depression & anxiety: Self-reported improved effect on their psychological status.
• 6MWD: Significant improvement.
• (HR)QoL: Difference between the DQoL–Social/Vocational Concerns subscale scores was statistically significant.
• Hospital readmissions: The 30-day hospital readmission rate was much lower, compared with the national readmission rates.
• Adherence: Significant improved medication adherence.

The list of results above is indicative and is only provided to showcase the potential and is not to be considered as a scientific outcome itself. Scientific results will be presented and analyzed in the Systematic Literature Review paper in the coming months, which will also include evidence and findings from studies that used Healthentia. By sharing our findings and experiences, we hope to contribute to the ongoing dialogue on digital health innovations and their role in transforming chronic disease management. Furthermore, the insights gained from the literature review and our benchmarking analysis may offer valuable guidance for healthcare providers, patients, and policymakers as they navigate the evolving landscape of digital health.

Looking ahead, the future of SaMD and mHealth applications appears promising, with the potential to significantly enhance the quality of care for patients with chronic diseases.

Sofoklis Kyriazakos, CEO

The post SaMD & mHealth apps: Status and promising results for improvement of health outcomes appeared first on Healthentia.